Update on HER-2 as target for cancer therapy. HER2/neu peptides as tumour vaccines for T cell recognition

Breast Cancer Research

Volumn 3, Issue 6, 2001, Pages 399-403

  Correa, Isabel ^a   Plunkett, Tim ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Cancer vaccines; HER2 neu peptides; Immunotherapy; Tumour antigens

Indexed keywords

AMINO ACID; CD4 ANTIGEN; CD8 ANTIGEN; EPITOPE; FREUND ADJUVANT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ONCOPROTEIN; PROTEIN ANTIBODY; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR VACCINE;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL SPECIFICITY; CLINICAL STUDY; CONTROLLED STUDY; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; ONCOGENE NEU; OVARY CANCER; T LYMPHOCYTE;

BREAST NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS; FEMALE; HUMANS; IMMUNOTHERAPY; PEPTIDES; RECEPTOR, ERBB-2; T-LYMPHOCYTES;

EID: 0035721814     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr330     Document Type: Article

References (27)

1. Update on HER-2 as a target for cancer therapy: Herceptin in the clinical setting
2. Challenges to the development of antigen-specific breast cancer vaccines
3. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
4. Progress in human tumour immunology and immunotherapy
5. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells
6. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors
7. Identification of an immunodominant peptide of HER-2/neu protooncogen recognized by ovarian tumor-specific cytotoxic T lymphocyte lines
8. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen
9. The makings of a tumor rejection antigen
10. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy
11. Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing
12. Clinical trials of HER2/neu-specific vaccines
13. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
14. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
15. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity
16. Impact of cytokine administration on the generation of anti-tumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
17. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
18. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors
19. The multiepitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors
20. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes
21. Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8
22. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinoma and melanomas
23. HER-2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer
24. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
25. Mapping ther HLA-A24-restricted T-cell epitope peptide from a tumour-associated antigen HER2/neu: Possible immunotherapy for colorectal carcinomas
26. A novel human HER2-derived peptide homologous to the mouse Kd-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals
27. A HER2/neu derived peptide, a Kd-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8+ cytotoxic T lymphocytes